There has recently been a growing interest in the sodium-glucose co-transporter 2 (SGLT2) inhibitors, a class of drugs used in the management of patients with type II diabetes.[1] This has derived largely because of their proven efficacy in increasing survival,[2,3] as well as reduction of body weight,[2,3] and risk of heart failure[4] in these cohorts of patients. This evidence concerns the gene SLC5A2 and heart failure.